KR880013572A - 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도 - Google Patents

인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도 Download PDF

Info

Publication number
KR880013572A
KR880013572A KR1019880005946A KR880005946A KR880013572A KR 880013572 A KR880013572 A KR 880013572A KR 1019880005946 A KR1019880005946 A KR 1019880005946A KR 880005946 A KR880005946 A KR 880005946A KR 880013572 A KR880013572 A KR 880013572A
Authority
KR
South Korea
Prior art keywords
insulin
component
mixed crystal
des
physiologically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019880005946A
Other languages
English (en)
Korean (ko)
Inventor
되르슈그 미카엘
오베르마이어 라이너
Original Assignee
하인리히 벡커, 베른하르트 벡크
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하인리히 벡커, 베른하르트 벡크, 훽스트 아크티엔게젤샤프트 filed Critical 하인리히 벡커, 베른하르트 벡크
Publication of KR880013572A publication Critical patent/KR880013572A/ko
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
KR1019880005946A 1987-05-22 1988-05-20 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도 Ceased KR880013572A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19873717370 DE3717370A1 (de) 1987-05-22 1987-05-22 Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
DEP3717370.7 1987-05-22

Publications (1)

Publication Number Publication Date
KR880013572A true KR880013572A (ko) 1988-12-21

Family

ID=6328227

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880005946A Ceased KR880013572A (ko) 1987-05-22 1988-05-20 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도

Country Status (20)

Country Link
US (1) US5028587A (https=)
EP (1) EP0291863B1 (https=)
JP (1) JPS63303930A (https=)
KR (1) KR880013572A (https=)
AT (1) ATE71842T1 (https=)
AU (1) AU601280B2 (https=)
CA (1) CA1335924C (https=)
DE (2) DE3717370A1 (https=)
DK (1) DK278088A (https=)
ES (1) ES2032896T3 (https=)
FI (1) FI93797C (https=)
GR (1) GR3004344T3 (https=)
HU (1) HU203840B (https=)
IE (1) IE60649B1 (https=)
IL (1) IL86452A (https=)
NO (1) NO175641C (https=)
NZ (1) NZ224715A (https=)
PH (1) PH25587A (https=)
PT (1) PT87523B (https=)
ZA (1) ZA883599B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK134189D0 (da) * 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
WO1992010284A2 (en) 1990-12-07 1992-06-25 Cnc Development, Inc. Catalytic chemical reactor
SG49239A1 (en) * 1991-05-24 1998-05-18 Amylin Pharmaceuticals Inc Amylin and possibly insulin containing composition for the treatment of aneroxia and related states
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5597893A (en) * 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
DE19903125B4 (de) * 1999-01-27 2006-01-05 Sanofi-Aventis Deutschland Gmbh Verfahren zur Trocknung von Kristallen von Insulin oder Insulinanaloga
CN1125081C (zh) 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
US7396936B1 (en) 2004-11-09 2008-07-08 Kemia, Inc. Modulators of calcitonin and amylin receptor activity
BRPI0717721A2 (pt) * 2006-11-28 2013-10-29 Marinus Pharmaceuticals "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
US9822158B2 (en) 2013-12-04 2017-11-21 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
EP3185887B1 (en) 2014-08-26 2021-03-10 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
EG12098A (en) * 1974-04-13 1980-12-31 Hoechst Ag New pharmaceutical insulin preparations having antidiabetic activity and process for their manufacture
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung

Also Published As

Publication number Publication date
NZ224715A (en) 1990-04-26
EP0291863A3 (en) 1990-04-04
PT87523A (pt) 1989-05-31
EP0291863B1 (de) 1992-01-22
JPS63303930A (ja) 1988-12-12
EP0291863A2 (de) 1988-11-23
ZA883599B (en) 1989-01-25
FI882354A0 (fi) 1988-05-19
FI882354L (fi) 1988-11-23
CA1335924C (en) 1995-06-13
IL86452A0 (en) 1988-11-15
IL86452A (en) 1993-02-21
DE3867903D1 (de) 1992-03-05
FI93797C (fi) 1995-06-12
NO175641C (no) 1994-11-09
HUT46546A (en) 1988-11-28
DK278088A (da) 1988-11-23
DE3717370A1 (de) 1988-12-01
IE881522L (en) 1988-11-22
NO882207L (no) 1988-11-23
NO882207D0 (no) 1988-05-20
GR3004344T3 (https=) 1993-03-31
HU203840B (en) 1991-10-28
US5028587A (en) 1991-07-02
IE60649B1 (en) 1994-08-10
DK278088D0 (da) 1988-05-20
ES2032896T3 (es) 1993-03-01
FI93797B (fi) 1995-02-28
AU1648788A (en) 1988-11-24
PT87523B (pt) 1992-09-30
ATE71842T1 (de) 1992-02-15
PH25587A (en) 1991-08-08
AU601280B2 (en) 1990-09-06
NO175641B (https=) 1994-08-01

Similar Documents

Publication Publication Date Title
KR880013572A (ko) 인슐린 및 인슐린 유도체의 혼합결정체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
Miller et al. Liver injury, liver protection, and sulfur metabolism: methionine protects against chloroform liver injury even when given after anesthesia
US4447355A (en) Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same
ATE66614T1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
ATE58292T1 (de) L-dopa enthaltendes arzneimittel.
KR890006644A (ko) 결정성 β-락탐 수화물
KR870006901A (ko) 인터로이킨-2 조성물의 제조방법
JPS6416724A (en) Stable and injectable vinca dimer salt solution
KR850001775A (ko) 인슐린 유도체의 제조방법
DE69808938D1 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen
KR860006982A (ko) 안정한 감마 인터페론 제형의 제조방법
KR880008801A (ko) 비경구 투여용 용액제
US4963529A (en) Stable growth hormone releasing factor preparation
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
KR910005886A (ko) 안정화 백혈구 인터페론
CA1289472C (en) Tpa-containing medical composition
GR3032156T3 (en) Treatment of human lactation failure.
DE3483784D1 (de) Verfahren zur herstellung von gamma-globulin zur intravenoesen anwendung.
GR890100737A (el) Μέ?οδος παρασκευής μιας φαρμακευτικής συν?έσεως δι'οφ?αλμική χρήσιν η οποία περιλαμβάνει ένα υδατοδιαλυτό άλας δια προσ?ήκης οξέος ιμποπαμίνης.
JP3262592B2 (ja) 〔Asu1.7〕カルシトニン類の水溶液注射剤の安定化法
JPS61267523A (ja) 安定な注射組成物およびそれらの製造方法
US4742082A (en) Solution of luprostiol and 1,2,-propanediol and methods of preparation and use
DE59002790D1 (de) Verfahren zur Herstellung einer Galenischen Zubereitung mit optimaler Bioverfügbarkeit des Wirkstoffs 2-Hydroxy-5-methyllaurophenonoxime (HMLO).
KR860000073A (ko) 기계적 응력에 대해 안정화된 수성인슐린 제제의 제조방법
JPH04503525A (ja) グリコシル化されていないt―PA誘導体K1K2Pproの製薬学的製剤および医薬品ならびに該製剤の製造方法

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19880520

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19930330

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19880520

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19951030

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19960131

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19951030

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I